Program
enfortumab vedotin
Also written as “Enfortumab Vedotin”, “Enfortumab vedotin” and “enfortumab vedotin (EV)”.
Its studies are mostly in Carcinoma, Transitional Cell · Urinary Bladder Neoplasms · Neoplasms · Triple Negative Breast Neoplasms · Non-Muscle Invasive Bladder Neoplasms, led by Astellas Pharma.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Astellas Pharma | 135 open or running | phase 4since Mar 3, 2025 | Jul 29, 2011 | Dec 31, 2026phase 4 · NCT06862219 |
Also a collaborator on its studies: Pfizer, Merck and Gilead Sciences.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 29, 2011First study: phase 1 study in NeoplasmsFirst studyNCT01409135 · 34 enrolled · United States, Canada
- Mar 18, 2014Phase 1 study in Metastatic Urothelial Cancer and Other Malignant Solid TumorsNCT02091999 · 213 enrolled · United States, Canada
- Mar 1, 2017Phase 1 study in Carcinoma, Transitional CellNCT03070990 · 19 enrolled · Japan
- Jul 13, 2017Phase 2 study in Carcinoma, Transitional CellNCT03219333 · 219 enrolled · United States, France, Germany and more
- Sep 18, 2017Phase 2 study in Carcinoma, Transitional CellNCT03288545 · 348 enrolled · United States, Canada, France and more
- Mar 16, 2018Phase 3 study in Ureteral NeoplasmsNCT03474107 · 608 enrolled · United States, Argentina, Australia and more
- Jan 6, 2020Phase 3 study in Urothelial CancerNCT04223856 · 886 enrolled · United States, Argentina, Australia and more
- Jan 9, 2020Phase 2 study in Triple Negative Breast NeoplasmsNCT04225117 · 329 enrolled · United States, Canada, Japan
- Aug 2, 2021Phase 2 study in Metastatic Urothelial CancerNCT04995419 · 40 enrolled · China
- Aug 16, 2021Phase 1 study in Urinary Bladder NeoplasmsNCT05014139 · 37 enrolled · United States, Canada, France and more
- Mar 3, 2025Phase 4 study in Carcinoma, Transitional CellNCT06862219 · 100 planned · India
- Mar 13, 2026Phase 2 study in Muscle-invasive Bladder CancerNCT07475806 · 240 planned · United States, Australia, Canada and more
- Apr 29, 2026Phase 3 study in Urinary Bladder NeoplasmsNCT07566156 · 390 planned · United States, Canada, South Korea and more
Ahead
- Dec 31, 2026Primary completion: phase 4 study in Carcinoma, Transitional CellNCT06862219
- Nov 30, 2027Primary completion: phase 2 study in Muscle-invasive Bladder CancerNCT07475806
- Mar 31, 2030Primary completion: phase 3 study in Urinary Bladder NeoplasmsNCT07566156
TargetBeta
“An antibody drug conjugate (ADC) containing a human monoclonal antibody AGS-22 targeting the cell adhesion molecule nectin-4 and ”NCIt, by rule
“Nectin-4 binding agent”ChEMBL 37, by rule
Other programs on NECTIN4
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| notiretatug rezetecan | Jiangsu HengRui Medicine | phase 3 | 14 |
| bulumtatug fuvedotinrule | Mabwell (Shanghai) Bioscience | phase 3 | 13 |
| Sutantatug Envedotinrule | CSPC Pharmaceutical Group | phase 3 | 6 |
| zelenectide pevedotinrule | bicycletx-limited | phase 2 | 5 |
| Anti-nectin-4 Antibody-drug Conjugate MK-3120rule | Merck | phase 2 | 5 |
| Anti-nectin-4/Anti-TROP2 Bispecific Antibody-drug Conjugate AVZO-103rule | avenzo-therapeutics-inc | phase 2 | 1 |
| Anti-nectin-4 Antibody-drug Conjugate IPH4502rule | innate-pharma | phase 1 | 1 |
| Anti-nectin-4/CD28 Bispecific Antibody RNDO-564rule | rondo-therapeutics | phase 1 | 1 |
| CT-202rule | context-therapeutics-inc | phase 1 | 1 |
Studies
All 13 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07566156Urinary Bladder Neoplasms · United States, Canada, South Korea and more | 3 | Recruiting | Mar 31, 2030 | 390 |
| NCT07475806Muscle-invasive Bladder Cancer · United States, Australia, Canada and more | 2 | Recruiting | Nov 30, 2027 | 240 |
| NCT06862219Carcinoma, Transitional Cell · India | 4 | Recruiting | Dec 31, 2026 | 100 |
| NCT05014139Urinary Bladder Neoplasms · United States, Canada, France and more | 1 | Terminated | Sep 22, 2025 | 37 |
| NCT04995419Metastatic Urothelial Cancer · China | 2 | Completed | May 13, 2022 | 40 |
| NCT04225117Triple Negative Breast Neoplasms · United States, Canada, Japan | 2 | Active, not recruiting | Feb 25, 2025 | 329 |
| NCT04223856Urothelial Cancer · United States, Argentina, Australia and more | 3 | Active, not recruiting | Aug 8, 2023 | 886 |
| NCT03474107Ureteral Neoplasms · United States, Argentina, Australia and more | 3 | Completed | Jul 15, 2020 | 608 |
| NCT03288545Carcinoma, Transitional Cell · United States, Canada, France and more | 2 | Terminated | Feb 20, 2026 | 348 |
| NCT03219333Carcinoma, Transitional Cell · United States, France, Germany and more | 2 | Completed | Oct 27, 2020 | 219 |
| NCT03070990Carcinoma, Transitional Cell · Japan | 1 | Completed | Feb 25, 2019 | 19 |
| NCT02091999Metastatic Urothelial Cancer and Other Malignant Solid Tumors · United States, Canada | 1 | Completed | Dec 7, 2022 | 213 |
| NCT01409135Neoplasms · United States, Canada | 1 | Completed | Apr 27, 2015 | 34 |
How it is read
Names in the registry
- “Enfortumab Vedotin”, 7 entries
- “Enfortumab vedotin”, 6 entries
- “enfortumab vedotin”, 3 entries
- “enfortumab vedotin (EV)”, 2 entries
- “Enfortumab vedotin (EV)”, 1 entry
Conditions, from the studies’ own filings
- Carcinoma, Transitional Cell, 7 studies
- Urinary Bladder Neoplasms, 5 studies
- Neoplasms, 2 studies
- Triple Negative Breast Neoplasms, 1 study
- Non-Muscle Invasive Bladder Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.